RNTX RNTX CMC Activities — Research And Development Expense

Other product segments

Similar metrics at other companies

LBR

LBRXFormulation And CMC — Direct Research And Development Expenses

$2.33M+257%

MPLTChemistry Manufacturing And Controls Expenses — Research And Development Expense

$6.42M+62.2%

GERNChemistry, manufacturing, and control expenses — R&D

$600K-60.0%

CSL

CSLCCM — Research and development expenses

$8.4M+3.7%

OSTXChief Operating Decision Maker — Research And Development Expense

$7.35M+462%

MPLTClinical Trial — Research And Development Expense

$24.82M+1,180%

Questions, answered.

What is RNTX's CMC activities — research and development expense?

RNTX (RNTX) reported CMC activities — research and development expense of $520K in Q1 2026.

How has RNTX's CMC activities — research and development expense changed year-over-year?

RNTX's CMC activities — research and development expense decreased by 7.1% year-over-year, from $560K to $520K.

What is the long-term trend for RNTX's CMC activities — research and development expense?

Over 2 years (2023 to 2025), RNTX's CMC activities — research and development expense has grown at a 223.5% compound annual growth rate (CAGR), from $214K to $2.24M.

What does CMC activities — research and development expense mean?

This metric represents the total costs incurred for Chemistry, Manufacturing, and Controls (CMC) activities associated with the development of specific therapeutic candidates. It captures expenditures related to process development, scale-up, and manufacturing quality control necessary to support clinical trials and regulatory filings. Monitoring these costs provides insight into the capital intensity and operational progress of the company's drug development pipeline.